New drug aims to supercharge immune system against HPV-Positive throat cancer

NCT ID NCT04852328

First seen Feb 06, 2026 · Last updated May 15, 2026 · Updated 18 times

Summary

This study tests an experimental drug called CUE-101 in 30 people with a specific type of HPV-positive throat cancer. The drug is given before standard treatments like surgery or chemoradiation to see if it safely boosts the body's immune cells to fight the cancer. Researchers will monitor side effects and measure immune responses in blood and tumor samples.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.